Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...

The new indications, approved Tuesday by the FDA, make Ozempic the most broadly indicated drug in its class, with the largest ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

The FDA on Tuesday approves Ozempic, the weight loss drug made by Novo Nordisk, for the treatment of chronic kidney disease ...

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

President Trump’s proposed tariffs on Denmark could have costly consequences for Americans relying on GLP-1 medications like Ozempic and Wegovy—and consumers are becoming increasingly concerned. While ...

When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical ...

The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and ...